Article: OrthoLogic Announces Label Changes for Hyalgan; Revised Package Insert Statements Extend Pain Relief Duration; Affirm Safety of Retreatment.

Business Editors &Health/Medical Writers

TEMPE, Ariz.--(BW HealthWire)--Jan. 24, 2000

OrthoLogic Corp. (Nasdaq:OLGC) today announced that the U.S. Food and Drug Administration has approved new labeling for Hyalgan that includes extended pain relief offered by a single course of therapy and no longer has safety restrictions on retreatment.

Hyalgan (sodium hyaluronate) is a product administered by injection directly into the knee joint for relief of pain in mild to moderate osteoarthritis of the knee. Hyalgan has been in use for more than 12 years, with approximately 5 million injections given to date, making it the world's most widely prescribed ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!